J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
Oncology, at present, comprises around 27% of J&J's total revenues. Its oncology sales rose 22.3% on an operational basis in the second quarter to $6.3 billion, driven by strong market growth and share gains of key products such as multiple myeloma treatment Darzalex and prostate cancer drug, Erleada. New cancer drugs, such as Carvykti, Tecvayli, Talvey and Rybrevant, plus Lazcluze, contributed significantly to growth as they witnessed strong launches.
Though the $50 billion target was well above consensus, J&J seems quite confident in the target, citing strong growth in its marketed cancer drugs and the potential of upcoming launches like TAR-200 in bladder cancer and the subcutaneous formulation of Rybrevant plus Lazcluze for advanced EGFR-mutated non-small cell lung cancer (NSCLC). TAR-200 is under priority review with the FDA for treating non-muscle invasive bladder cancer and is expected to be approved this year. The subcutaneous formulation of Rybrevant plus Lazcluze has been recommended for approval in the EU while it is under review in the United States.
Meanwhile, J&J's oncology pipeline has gained strong momentum in the last year and a half, with promising developments in colorectal and head and neck cancers. In this period, J&J had eight proof-of-concept readouts, which led the candidates to move to late-stage pivotal studies across the portfolio. If these pipeline drugs are eventually approved, they can also boost JNJ's oncology sales.
In the five years from 2019 to 2024, J&J's oncology sales have doubled from $10.7 billion in 2019 to $20.8 billion in 2024. To achieve the $50 billion target in the next 5-6 years, the company needs to more than double its sales from 2024 levels. Though quite optimistic, the target is not unachievable.
Competition in the Oncology Space
Other large players in the oncology space are Pfizer PFE, AstraZeneca AZN, Merck MRK and Bristol-Myers.
Pfizer boasts a strong portfolio of approved cancer medicines like Xtandi, Lorbrena and the Braftovi-Mektovi combination. The addition of Seagen in 2023 also strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. Pfizer also has a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics.
For AstraZeneca, oncology sales now comprise around 41% of total revenues. AstraZeneca's strong oncology sales growth is being driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates.
Merck's key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales.
Bristol-Myers' key cancer drug is PD-LI1inhibitor, Opdivo, which accounts for around 20% of its total revenues.
JNJ's Price Performance, Valuation and Estimates
J&J's shares have outperformed the industry year to date. The stock has risen 14.6% in the year-to-date period compared with an increase of 1.5% for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.97 forward earnings, slightly lower than 15.04 for the industry. The stock is also trading below its five-year mean of 15.70.
The Zacks Consensus Estimate for 2025 earnings has risen from $10.60 per share to $10.66 over the past 30 days, while that for 2026 has risen from $10.98 to $11.13 over the same timeframe.
J&J has a Zacks Rank #2 (Buy) currently. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
After months of uncertainty U.S. and EU reach trade deal
Watch The U.S. and the European Union have reached a trade deal that imposes a 15% tariff on most EU exports to the U.S.
Globe and Mail
an hour ago
- Globe and Mail
Amber Kanwar's Weekly Setup: Big tests are coming for the markets
My husband got taken down by a nasty summer bug but has reintegrated into the family. He stayed in the guest room to avoid infecting me and the kids. He passed his time watching TV and having meals delivered. I'm glad he is back in the fold, but I would be lying if I didn't admit there is a small part of me that thought about licking one of his spoons to get a few days alone in a quiet room. This is not the week to call in sick with huge catalysts on deck. Here are the five things to watch: Magnificent week: With the S&P 500 sitting atop a record high, the resilience of the Magnificent 7 (also at a record) will be the next test for the markets. Four of the seven companies report this week, including Meta Platforms Inc. META-Q, Microsoft Corp. MSFT-Q, Apple Inc. AAPL-Q and Inc. AMZN-Q They represent a combined US$14-trillion in value. The big question for all of them will be how much each company is spending on AI. Although for Apple, it will be more like, 'Have you heard of AI?' Apple is the second-worst-performing Mag7 after Tesla Inc. TSLA-Q, down about 14 per cent so far in 2025. The reason Apple is in the dog house is because it lacks a clear AI strategy, according to Needham senior analyst Laura Martin. She said 'calls to replace Tim Cook as Apple CEO are getting louder every quarter that Apple doesn't lay out a comprehensive GenAI strategy.' After Alphabet Inc. GOOGL-Q surprised investors with a US$85-billion spending plan, there is a good chance the others follow suit. Is it any wonder that Nvidia Corp. NVDA-Q is back at a record high and the best-performing Magnificent 7 in 2025? Decisions, decisions: If mega-cap earnings weren't enough, the Bank of Canada and U.S. Federal Reserve are delivering interest-rate announcements on Wednesday. The BoC is expected to keep rates on hold at 2.75 per cent for a third time in a row. Core inflation, which is hanging around 3 per cent, and the oddly robust jobs data from earlier this month make it an easy bet that the BoC will hold. It is also an easy bet that the Federal Reserve won't cut this month, although U.S. President Donald Trump may think otherwise after meeting with Fed Chair Jerome Powell this week on a tour of the central bank's renovations. Mr. Trump said Mr. Powell congratulated him on a strong economy, which he took to mean that rate cuts are coming. Watch for dissenters on the decision; those are the ones auditioning for Mr. Powell's job when his term expires next year. Hold your breath: In the past three months, UnitedHealth Group Inc. UNH-N has slashed its profit forecast, announced that its CEO is leaving, then suspended its profit forecast altogether and endured a 50-per-cent drop in the value of its shares. And just last week, it confirmed that it is the subject of a Department of Justice investigation into its Medicare practices. Talk about a season to forget. The embattled health insurer is set to report quarterly results Tuesday morning as its stock languishes at the lowest level in five years. However, that now means it sports a low-teens multiple. Before you let that lure you in, like yours truly, value investor Michael McCloskey, founder and president of GreensKeeper Asset Management, said on my podcast this week that this has the markings of a value trap. 'When you see the suggestion that maybe they're playing games with Medicare, it's the cockroach theory,' he said. 'I might be totally wrong, but when I see that, I tend to stay away.' Flying close to the sun: Bombardier Inc. BBD-B-T reports this week and talk about a comeback story. The stock is up 1,400 per cent over the past five years compared with just 100 per cent for the TSX over that time. It went from a universally unloved stock with high debt levels to a Bay Street favourite with a new investment-grade debt rating. Its transformation into a business-jet company has paid off big time. But some analysts say the setup from here gets harder. TD Cowen analyst Tim James downgraded the stock last week on the runup and says it has a bad habit of falling on earnings days regardless of the results. '[The] recent share-price strength may heighten Q2 hurdle for driving further short-term upside,' said Mr. James in a note downgrading the stock from buy to hold. Hot commodity: MEG Energy Corp. MEG-T reports results Thursday after the close. The energy producer is subject to a hostile bid from Strathcona but reports last week suggest Cenovus is preparing a rival bid. The company will likely be tight lipped about what it can say, but analysts and investors may pry to see where the companies are in the process and how many other bidders have kicked the tires. In the Money with Amber Kanwar brings you actionable insights from top portfolio managers and business leaders. New episodes out Tuesdays and Thursdays. Subscribe now!
Globe and Mail
2 hours ago
- Globe and Mail
Better Quantum Computing Stock: IonQ vs. Rigetti Computing
Key Points IonQ and Rigetti Computing have developed fundamentally different methods to create quantum computers. IonQ aspires to build the internet of the future while Rigetti focuses on commercializing its superconducting qubit technology. Neither IonQ nor Rigetti are profitable, although they have amassed large sums of cash to fund their operations. 10 stocks we like better than IonQ › The quantum computing industry is a promising area to invest in. Quantum machines can complete complex calculations in minutes that would take classical computers centuries, thanks to the power of quantum mechanics. In the sector, IonQ (NYSE: IONQ) and Rigetti Computing (NASDAQ: RGTI) are among the prominent players. IonQ uses ions to power its quantum machines while Rigetti employs the traditional superconducting qubits process. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Both have seen impressive share price increases over the past year. IonQ stock is up over 400% through July 23 while Rigetti climbed more than 1,000% in that time. Is one a better investment in the nascent quantum computing field? Examining these businesses in more detail can help to arrive at an answer. Rigetti Computing's tried-and-true tech Rigetti uses a proven method of producing qubits. Qubits are a quantum device's equivalent to a classical computer's bit. But while bits represent a zero or one, the properties of quantum mechanics mean qubits can be both at the same time, enabling orders of magnitude faster processing speeds. Superconducting qubits offer several advantages. They can be manufactured using existing semiconductor chip processes, and can complete calculations faster than ion-based quantum machines. Rigetti hopes to gain greater commercialization with the latest version of its quantum computer, the Ankaa-3 system, which launched at the end of 2024. However, the technology isn't cheap. Superconducting qubits require special cryogenic equipment to keep temperatures colder than outer space. This is necessary for qubits to maintain stability long enough to perform calculations before they break down. As a result, the company exited the first quarter with an operating loss of $21.6 million on sales of $1.5 million. The loss is 30% greater than the previous year while Q1 revenue plunged 52% year over year. This combination of falling revenue and rising costs is unsustainable over the long run. That's why Rigetti executed a $350 million equity offering that helped it build up a stockpile of $575 million in cash, cash equivalents, and investments with no debt as of June 11. This cash hoard should sustain the company's operations in the short term, but it will need to produce revenue growth to build a sustainable business. IonQ's lofty ambition to remake the internet IonQ's ion-based method holds several advantages over superconducting qubits. Its tech can operate at room temperature, eschewing the need for cryogenic equipment. The technology also offers low error correction rates. Because qubits quickly break down, quantum computers are prone to calculation mistakes that limit their ability to scale. IonQ's reduced error rates make scalability a possibility. Consequently, the company aims to construct a quantum computing network, reminiscent of the infrastructure that underpins today's world wide web. It pursued several acquisitions to achieve its goal of building "the next generation of the internet," in the words of IonQ Chairman Peter Chapman. But like Rigetti, IonQ's costs are rising. It posted a Q1 operating loss of $75.7 million, an increase from 2024's $52.9 million, on revenue of $7.6 million. So it, too, is pursuing an equity offering to the tune of $1 billion. In addition, IonQ believes it can hit revenue of $75 million to $95 million in 2025. This would be a strong increase over 2024, when sales soared 95% year over year to $43.1 million. Making the choice between IonQ and Rigetti Computing stock Although Rigetti's superconducting qubits technology is well established in the quantum computing industry, IonQ's approach is producing higher sales. On top of that, another factor to consider is share price valuation. This can be assessed using the price-to-sales (P/S) ratio, a metric commonly used when companies are not profitable. Data by YCharts. The chart reveals Rigetti's P/S multiple has skyrocketed from where it was a year ago, and is far higher than IonQ's as well. This suggests Rigetti stock is overpriced, making IonQ the better value. That said, IonQ stock is not cheap, given it has a P/S ratio exceeding 200. While quantum computers hold the promise of revolutionizing the computing industry, whether IonQ or Rigetti's approach will win out in the end is far from certain. After all, quantum computing is still in its infancy. Its market size was just $4 billion in 2024, although industry estimates predict rapid growth to $72 billion by 2035. As of now, IonQ's 2024 sales success coupled with an outlook of 2025 revenue growth, and a far better valuation compared to Rigetti, make its stock the superior quantum computing investment between these two businesses. Ideally, wait for a dip in IonQ's share price, and for its Q2 results to validate it's on a trajectory to hit 2025 sales targets before deciding to pick up shares. Should you invest $1,000 in IonQ right now? Before you buy stock in IonQ, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and IonQ wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
